GRAd-COV2
GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases. It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.
More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1247441281 under CC BY-SA 4.0; modifications have been made.